Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).

about

Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).

Item

http://www.wikidata.org/entity/Q55403230

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Practical consensus recommenda ...... arly breast cancer (adjuvant).

@en

Practical consensus recommendations on ovarian suppression in early breast cancer

@nl

type

Item

label

Practical consensus recommenda ...... arly breast cancer (adjuvant).

@en

Practical consensus recommendations on ovarian suppression in early breast cancer

@nl

prefLabel

Practical consensus recommenda ...... arly breast cancer (adjuvant).

@en

Practical consensus recommendations on ovarian suppression in early breast cancer

@nl

P1476

Practical consensus recommenda ...... arly breast cancer (adjuvant).

@en

P2093

A Singhvi

http://www.w3.org/2001/XMLSchema#string

A Vora

http://www.w3.org/2001/XMLSchema#string

K M Parthasarthi

http://www.w3.org/2001/XMLSchema#string

M Ganvir

http://www.w3.org/2001/XMLSchema#string

M Singhal

http://www.w3.org/2001/XMLSchema#string

Purvish M Parikh

http://www.w3.org/2001/XMLSchema#string

S Aggarwal

http://www.w3.org/2001/XMLSchema#string

S Gupta

http://www.w3.org/2001/XMLSchema#string

S Rajpurohit

http://www.w3.org/2001/XMLSchema#string

T P Sahoo

http://www.w3.org/2001/XMLSchema#string

P2860

Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.

Cancer statistics, 2002

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.

Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

P304

151-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/SAJC.SAJC_125_18

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29721484

http://www.w3.org/2001/XMLSchema#string

P932

5909295

http://www.w3.org/2001/XMLSchema#string